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Introduction: Preeclampsia is a complication affecting pregnant women worldwide, 
which leads to maternal and fetal morbidity and mortality. Due to the importance of 
mutations in the PLGF (Placental Growth Factor) gene and the association with the 
incidence of preeclampsia, this study aimed to evaluate the association of 
polymorphisms of the PLGF gene with the prevalence of preeclampsia in Iranian 
women. 
Methods: Fifty pregnant women with pre-eclampsia diagnosis and 50 healthy pregnant 
women for determination of genotypes rs1464547123, rs12411, rs1399853427, and 
rs1312670436 were evaluated using the Sanger sequencing method. 
Results: There was no significant difference in the frequency of alleles of 
rs1464547123, rs1399853427 and rs1312670436 polymorphisms between case and 
control groups (P > 0.05), but the rate of recessive allele A in rs12411 polymorphism 
was significantly higher in the case group than in the control group (case = 24%, control 
= 8%, P-Value = 0.04), while the frequency of the allele T in the control group was 
higher than that of the patient group (case = 76%, control = 92%, P-Value = 0.04) The 
frequency of AT genotype in the patient group was a none significantly higher than the 
control group (case = 8%, control = 4%, P-Value = 0.1) and the frequency of AA 
genotypes in the case group was none significantly higher than that of the control group 
(case = 16%, control = 4%, P-Value = 0.1). 
Conclusions: The results revealed that polymorphism rs12411 of the gene encoding 
PLGF has a significant difference among individuals with and without pre-eclampsia 
and can affect the incidence of pre-eclampsia among Iranian women. 
Keywords: 
Polymorphism, Genetic 
Placenta Growth Factor 
Pre-Eclampsia 
© 2020. International Journal 
of Cardiovascular Practice. 
INTRODUCTION
Preeclampsia is a common and serious hypertensive 
disorder affecting approximately 5% of pregnancies. The 
biology of the disease is complex and not understood 
[1]. This disease associated with increased blood 
pressure more than 140/90 mmHg in the second half of 
pregnancy and proteinuria (protein excretion in the 
urine) more than 300 mg/24 h and is considered as one 
of the three leading causes of maternal and fetal 
mortality and related complications [2]. This 
complication is a systemic disorder and can lead to 
difficulties in the mother, such as kidney and liver 
dysfunction, cerebral edema associated with seizure and 
affliction to HELLP syndrome (hemolysis elevated liver 
enzymes and low platelet count). As well as, the risk of 
injury in the fetus, such as fetal growth restriction, which 
is considered as one of the most important causes of 
neonatal mortality, is common [3, 4]. Expulsion of the 
fetus and placenta from the mother’s body eliminates 
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the symptoms of the disease. Still, the complications of 
the disease can be problematic for the child and mother 
until the end of life. Among these are the risks of 
afflicting mother to cardiovascular and metabolic 
diseases [5]. There are two types of pre-eclampsia: mild 
and severe. The severe pre-eclampsia type is 
characterized by a diastolic blood pressure of 110 mm 
Hg or more, higher proteinuria, high creatinine, 
increased liver enzymes and headache, oliguria, 
pulmonary edema, upper abdominal pain, visual 
impairment, and thrombocytopenia [6]. Various factors 
are involved in the onset of this disease including 
Vascular activating proteins, oxidative stress, 
endothelial damage, immunogenic disorders, 
thrombophilia, and other cases [5, 6]. Women with a 
history of preeclampsia have approximately double the 
risk for subsequent ischemic heart disease, stroke and 
venous thromboembolic events over the 5 to 10 years 
following the pregnancy [7, 8]. 
Although most cases of preeclampsia are sporadic, 
genetic factors are thought to play a role in disease 
susceptibility. More than 70 candidate preeclampsia-
related genes have been studied. Placental Growth 
Factor (PlGF) is essential member of the VEGF 
(Vascular endothelial growth factor), family with a 
molecular weight of 75.13 kb. PlGF was proposed to 
regulate vascular development and trophoblast growth 
and differentiation. PlGF is responsible for placentation, 
and it is believed to play its role as antigenic [7]. Unlike 
VEGF which is required for angiogenesis and 
endothelial cell maintenance, PlGF is redundant for 
vascular development and selectively binds Flt-1/ sFlt-1 
(soluble FMS-like tyrosin kinase-I). PlGF is necessary 
for stimulating endothelial cell growth, migration, and 
survival and plays a primary role in pathologic 
angiogenesis, including in cancer and tissue ischemia 
[8]. In healthy pregnancy, PlGF level increases in serum 
significantly [9]. In the placenta, it is expressed in giant 
trophoblast cells and decidua natural killer cells [10]. 
Although it is dispensable for embryogenesis, recent 
data support its function in fetal cerebrovascular 
development [11]. Compared with normotensive 
controls, circulating levels of sFlt-1 is increased, and free 
VEGF and free PlGF are decreased before the onset of 
clinical disease in preeclamptic women [12, 13]. 
Reducing levels of PlGF serum in the first trimester 
causes angiogenesis placenta imbalance, which leads to 
preeclampsia in the second or third trimester [14].  
Today, a large number of women are suffering from 
preeclampsia during pregnancy. Unfortunately, the 
leading causes of this disease have not yet been known, 
which it seems that the mutation in the PlGF gene is one 
of the leading causes of the disease [15]. 
This study aimed to examine the polymorphisms of the 
PLGF gene in preeclamptic women compared with 
healthy pregnancies. Regarding the importance of the 
issue, we attempted to obtain enough statistical 
information to consider single nucleotide 
polymorphisms (SNPs) for identifying individuals 
predisposed to the disease through identifying possible 




This study was approved by the Ethics committee of 
Islamic Azad University- Science and research branch 
(Approval number: IR.I-AU.SRB.REC.1397.111). 
Study design and patients: This is a case-control study in 
which a total of 50 women with preeclampsia (approved 
by medical history results) versus 50 healthy women 
include pregnant women without a history of 
hypertension and on average with 110 mmHg systolic 
blood pressure and 70 diastolic blood pressure (without 
history of preeclampsia) referring to hospitals in Tehran 
were examined between the years 2017 to 2018. All 
patients provided written informed consent.  
Exclusion criteria included the history of cardiovascular 
disease and metabolic disease, history of hypertension 
before pregnancy, history of smoking and cigarette and 
chronic hypertension, and kidney disease. Sanger 
sequencing method was used to determine the 
genotypes. The amount of 5 ml peripheral blood 
samples were collected from patients, divided into 
clotting tubes for serum separation and in other tubes 
containing EDTA (Ethylenediaminetetraacetic acid) 
anticoagulant for DNA extraction. Blood samples were 
stored at a temperature of -20°C. 
 
Table 1. The Primers Sequences for the PlGF Gene 
 Primer Sequences Product 
length 
Exon1 3΄CTGGCTAGGAATCCCTTGG5́ 1001bp 
 3΄TTCCCAAACGAAAGAAGTCC5́  
Exon2 3΄GCAGCAAGTGGGAAGGAACC5́ 614bp 
 3΄ATGGAAACGCATGGTCAGATC5́  
Exon3 3΄TTCCATCCAACAGATGAGC5́ 660bp 
 3΄GACTTCATACAAGCAGATTTCT5 ́  
Exon6 3΄ATGAAGCCGGAAAGGTAA5΄ 332bp 
 3΄GCCCTAGAGTCTTGAGGA5΄  
Exon7 3ˋTGAGGGTTAAGAAGACAGTG5ˋ 1272bp 
 3ˋCGAGGCTTTTGAGATAAGG5́  
 
Polymerase chain reaction (PCR) and sequencing: 
The PCR reaction was performed in 25 μl volume 
containing 100-300 ng of extracted DNA, 1X PCR 
buffer (50 mM KCl; 10 mM Tris-HCl; 1.5 mM MgCl2), 
2 mM MgCl2, 200 µM dNTP mix, and double-distilled 
water was added up to 25 µl with 1 U of Taq DNA 
polymerase (super Taq DNA polymerase, Gen 
Fanavaran co., Tehran, Iran) and 0.4 µM of each 
oligonucleotide primer in Thermocycler (Eppendorf-
Nexus-Germany). PCR program was performed as the 
first denaturation in 95ºC for 5 min, Denaturation in 
95ºC 30s, Annealing in 58ºC 30s, Elongation 72ºC 30s, 
Final extension 72ºC 5min. PCR products were loaded 
on 1% agarose gel followed by ethidium bromide 
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staining to confirm the detected, amplified fragments 
(Primers were summarized in Table 1). 
To determine the genotypes of PCR products, samples 
were sent to the sequence that ultimately the results 
obtained from the charts of the sequenced examples 
were examined by Finch TV software, and the accuracy 
of the work was confirmed. 
Statistical analysis: SPSS software version 20 was used 
for data analysis, and only 5% was considered as an 
acceptable rate of the type 1 error. The SHEsis software 
was used to examine the Hardy-Weinberg equilibrium. 
Also, given the status of data distribution, Independent 
samples t-test, Mann-Whitney U, and one-way ANOVA 
or Kruskal-Wallis were used. Odds ratios (OR) with 
95% confidence intervals were calculated to determine 
the odds of developing preeclampsia when the 
individual has the gene variants of interest. Values of P < 
0.05 were considered statistically significant. 
RESULTS 
The demographic and clinical characteristics of the 
subjects are presented in Table 2. The results of this 
study showed that there was a significant difference 
between the two groups of patients and control in terms 
of weight and blood pressure. So that the weight in the 
patient group was significantly higher than that of the 
control group (P < 0.001, OR = 2.55). As well as, 
according to this study, it was found that systolic blood 
pressure (P < 0.001) and diastolic blood pressure (P < 
0.001) had a significant difference between the two 
groups, so that blood pressure in the patient group was 
higher than the control group, but there was no 
significant difference in body mass index (P = 0.1, OR = 
0.57) and age (P = 0.2, OR = 0.36) between both case 
and control groups (Table 2). 
 
 
Table 2. Anthropometry and blood pressure data in both patient (case) and control groups 
Characteristics Case group Control group OR (CI 95%) P value 
Age, (years) 25.8 (7.16) 24.7 (6.22) 0.36 0.2 
Gestational age, (weeks) 32.9 (4.02) 33.1 (4.71) 0.45 0.7 
Gestational weight gain, (kg) 12.7 (8.50-16.50) 10.0 (6.75-13.55) 2.55 0.003 
Systolic blood pressure, (mmHg) 170 (160.0-180.0) 110 (100.0-120.0) 6.00 < 0.001 
Diastolic blood pressure, (mmHg) 110 (100.0-120.0) 70 (70.0-80.0) 6.05 < 0.001 
Body mass index, (kg/m2) 25.05 (21.63-28.13) 23.35 (20.53-26.90) 0.57 0.1 
Data presented as mean (SD) or median (ranges) 
 
PCR product bands were determined in Figure 1. 
Sanger Sequencing data for PLGF gene and comparing 
it with the reference genome in the Ensemble database 
indicated that there are four single nucleotide 
polymorphisms in the case groups of Exon7. These 
SNPs include rs12411, rs869273721, rs1472556360, 
rs1169394182. Variants rs869273721 and 
rs1169394182 have been shown as intronic deletions, 
A/- and C/- respectively, that were without clinical 
significance and reported only in one and two patients, 
and these variants were considered rare. Also, 
rs1472556360 is a T/A SNP found in 3ˋ UTR of exon 
number 7 and was reported only in one patient and 
considered rare. Rs12411 was reported in 6 of 25 
patients (24%). Therefore it was considered as a 
common variant. There were three single nucleotide 
polymorphisms in the case groups of exon6 include 
rs1464547123, rs937495410 and rs1048230880. 
Rs1464547123 is a TT/TA SNP that has been found in 
the intron of exon number 6 and were reported in 8 of 
25 patients (32%). Therefore it was considered a 
common variant. There were four single nucleotide 
polymorphisms in Exon 3 in the case groups. 
Rs772978877, rs1157624583 and rs756979630 were 
alternative variants without any clinical significance and 
rs1157624583 reported in 6 of 25 patients (24%). There 
were four variants in Exon 2 in the case group. 
Rs772978877, rs1369722917 and rs761111694 as a 
Shuffle change without any clinical significance have 
been seen in one of the patients and the variant 
rs1399853427 was reported in 4 of 25 cases (16%) 
(Tables 3 and 4). 
 
Figure 1. Polymerase chain reaction amplification. Fragments of the 
gene were detected after electrophoresis on 1% agarose gel. The 
Housekeeping gene is GAPDH 
 
DISCUSSION 
Preeclampsia is known to be the third cause of maternal 
death worldwide. The incidence of preeclampsia has 
increased probably due to the prevalence of disorders 
such as hypertension, diabetes, and obesity [16]. 
Approximately one-tenth of all maternal mortality in 
Africa, Asia, and a quarter in Latin America is associated 
with diseases like hypertension during pregnancy. 
Preeclampsia is prevalent in the first pregnancy. Women 
with preeclampsia in their early pregnancy are more 
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likely to develop preeclampsia in their later pregnancies. 
Women with high blood pressure, obesity, diabetes, and 
autoimmune diseases such as lupus, as well as various 
hereditary thrombophilia such as leukemia Factor V, 
kidney disease, multiple pregnancies (twin or more), 
and high maternal age, are a greater risk for 
preeclampsia. PlGF plays an important role in the 
angiogenesis of natural tissues and also in tumors, the 
lack of which is associated with angiogenesis deficiency 
[17, 18]. 
 
Table 3. All variants have been seen in exon 2, 3, 6 and 7 
Variants Nucleotide change Mutation site Abundance, N = 25 
Exon 2  
rs1399853427 C/T Trimming 4 (16) 
rs772978877 T/C Trimming 1 (4) 
rs1369722917 -/T Trimming 1 (4) 
rs761111694 G/A Meaningful variant in intron 1 (4) 
Exon 3  
rs756979630 -/G Trimming 1 (4) 
rs772978877 T/C Replacement 1 (4) 
rs1157624583 C/T Synonym Variant 1 (4) 
rs1312670436 G/C Replacement 6 (24) 
Exon 6  
rs1464547123 TT/TC Trimming 8 (32) 
rs937495410 C/- Deleting introns 1 (4) 
rs1048230880 A/- Deleting introns 1 (4) 
Exon 7  
rs12411 A/T 3 UTR 6 (24) 
rs869273721 A/- Deleting introns 1 (4) 
rs1472556360 T/A 3 UTR 1 (4) 
rs1169394182 C/- Deleting introns 2 (8) 
Data in table are presented as No. (%). 
 
Table 4. Results of Allele and Genotype Frequency Distribution in the most frequent single nucleotide polymorphism (SNP) in the PlGF gene. 
Allele /Genotype Case (N=25) Control (N=25) OR (95 CI) P value 
rs12411, exon7  
A 6 (24) 2 (8) 1.46 (1.22-1.56) 0.04 
T 19 (76) 23 (92)   
AA 4 (16) 1 (4) 1.26 (1.08-2.40) 0.1 
AT 2 (8) 1 (4)   
TT 19 (76) 23 (92)   
rs1464547123, exon6  
C 17 (68) 5 (20) 1.13 (1.06-1.56) 0.08 
T 7 (28) 20 (80)   
CC  3 (12) 1.2 (1.30-2.40) 0.1 
CT 1 (4) 2 (8)   
TT 17 (68) 20 (80)   
rs1312670436, Exon3  
G 6 (24) 2 (8) 1.22 (1.08-1.56) 0.8 
C 19 (76) 23 (92)   
GG 3 (12) 2 (8) 1.31 (1.12-1.64) 0.1 
GC 3 (12) 0 (0)   
CC 19 (76) 23 (92)   
Rs1399853427, Exon2  
C 4 (16) 1 (4) 1.09 (1.01-1.36) 0.2 
T 21 (84) 24 (96)   
CC 3 (12) 1 (4) 1.01 (1.00-1.19) 0.3 
CT 1 (4) 0 (0)   
TT 21 (84) 24 (96)   
Data in table are presented as No. (%). 
 
PlGF involved in cardiovascular disease, infectious 
diseases and increases the internal thickness of 
atherosclerosis. Several studies have shown the critical 
role of PlGF in pathologic conditions such as ischemia, 
tumor formation, cardiovascular disease, and 
inflammatory processes [19]. In one study, changes in 
plasma PlGF were assessed in two groups. Results 
showed a strong association between elevated PlGF 
with age and gender. Then, the relationship between 
single nucleotide polymorphisms (SNPs) in PlGF and 
its plasma levels was investigated. Two polymorphisms 
rs11850328 and rs2268614 showed a significant 
relation with PlGF plasma levels. 
The present study aimed to investigate the exons of the 
PlGF gene in women with preeclampsia. The results of 
our research in exon 7, variants rs869273721 and 
rs1169394182 have been shown an intronic deletion in 
one and two patients, respectively, and the variant is 
considered rare without clinical importance. Also, the 
rs1472556360 option was seen as a single nucleotide 
replacement in one patient, which was reported as a rare 
variant. In exon six have been shown three single-
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nucleotide variants that rs937495410 and 
rs1048230880 variants were rarely reported and single-
nucleotide polymorphism rs1464547123 was more 
common in both control and control groups. 
In a similar study, Vodolazkaia et al. examined the effects 
of single nucleotide polymorphisms in the angiogenesis 
and its association with endometriosis. These genes 
included VEGF, PLGF, VEGFR1, and HIF-1a. The 
results of this study showed that there was a significant 
relationship between rs2268613 polymorphism in the 
PLGF gene and endometriosis. Women with AA 
genotype had a lower level of their blood PLGF than 
those with AG genotype [20]. 
In the present study, rs12411 have been reported in 
exon 7 in 6 of 25 patients and 2 healthy subjects. Sorice 
R et al. examined a total of 1812 European female 
patients with PLGF gene polymorphisms in a cohort 
study. The five SNPs located in the PGF gene region 
were: the rs12411, rs8185 and rs2268613 
polymorphisms placed in the 39 regulative region; the 
rs2268614 variant located in intron 3 and the 
rs11850328 variant located in the region upstream the 
PGF gene. The results of this study showed that three 
polymorphisms rs12411, rs11850328 and rs2268614 
were significant in the studied population [21]. 
Conclusion: This study aimed to investigate the PLGF 
gene in women with preeclampsia. Four common 
variants rs12411, rs1464547123, rs1399853427 and 
rs1312670436 were reported in these patients. 
According to the statistical results, it is necessary to use 
the number of more people in this test to establish a 
meaningful relationship between preeclamptic patients. 
It is suggested that the variants of the present study be 
repeated with a larger sample size in Iranian women to 
get better results. 
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